Influenza update 2018–2019: 100 years after the great pandemic

ABSTRACT

Four influenza pandemics, starting with the historic 1918 pandemic, have killed thousands of people around the world. Vaccination, still the most important means of preventing influenza, is currently recommended yearly for all people age 6 months and older, with a goal of vaccinating 80% of all Americans and 90% of at-risk populations. Neuraminidase inhibitors are underused, and a new drug with a different mechanism of action, baloxavir marboxil, is expected to be approved soon in the United States.

KEY POINTS

- Influenza A(H7N9) is a prime candidate to cause the next influenza pandemic.
- Influenza vaccine prevents 300 to 4,000 deaths in the United States every year.
- The 2018–2019 quadrivalent influenza vaccine contains updated A(H3N2) and B/Victoria lineage components different from those in the 2017–2018 Northern Hemisphere vaccine.
- The live-attenuated influenza vaccine, which was not recommended during the 2016–2017 and 2017–2018 influenza seasons, is recommended for the 2018–2019 influenza season.
- Influenza vaccine is recommended any time during pregnancy and is associated with lower infant mortality rates.
- Overall influenza vaccination rates remain below the 80% target for all Americans and 90% for at-risk populations.

This year marks the centennial of the 1918 influenza pandemic, which killed 50 million people worldwide. Three more influenza pandemics and annual epidemics have occurred since then, with other significant interim events (Table 1). The 2017–2018 epidemic was particularly severe and long.

This centennial year update focuses primarily on immunization, but also reviews epidemiology, transmission, and treatment.

EPIDEMIOLOGY

2017–2018 was a bad season

The 2017–2018 influenza epidemic was memorable, dominated by influenza A(H3N2) viruses with morbidity and mortality rates approaching pandemic numbers. It lasted 19 weeks, killed more people than any other epidemic since 2010, particularly children, and was associated with 30,453 hospitalizations—almost twice the previous season high in some parts of the United States.

Regrettably, 171 unvaccinated children died during 2017–2018, accounting for almost 80% of deaths. The mean age of the children who died was 7.1 years; 51% had at least 1 underlying medical condition placing them at risk for influenza-related complications, and 57% died after hospitalization.

Recent estimates of the incidence of symptomatic influenza among all ages ranged from 3% to 11%, which is slightly lower than historical estimates. The rates were higher for children under age 18 than for adults. Interestingly, influenza A(H3N2) accounted for 50% of cases of non-mumps viral parotitis during the 2014–2015 influenza season in the United States.

doi:10.3949/ccjm.85a.18095
Influenza C exists but is rare
Influenza A and B account for almost all influenza-related outpatient visits and hospitalizations. Surveillance data from May 2013 through December 2016 showed that influenza C accounts for 0.5% of influenza-related outpatient visits and hospitalizations, particularly affecting children ages 6 to 24 months. Medical comorbidities and copathogens were seen in all patients requiring intensive care and in most hospitalizations. Diagnostic tests for influenza C are not widely available.

Dogs and cats: Factories for new flu strains?
While pigs and birds are the major reservoirs of influenza viral genetic diversity from which infection is transmitted to humans, dogs and cats have recently emerged as possible sources of novel reassortant influenza A. With their frequent close contact with humans, our pets may prove to pose a significant threat.

Obesity a risk factor for influenza
Obesity emerged as a risk factor for severe influenza in the 2009 pandemic. Recent data also showed that obesity increases the duration of influenza A virus shedding, thus increasing duration of contagiousness.

Influenza a cardiovascular risk factor
Previous data showed that influenza was a risk factor for cardiovascular events. Two recent epidemiologic studies from the United Kingdom showed that laboratory-confirmed influenza was associated with higher rates of myocardial infarction and stroke for up to 4 weeks.

Which strain is the biggest threat?
Predicting which emerging influenza serotype may cause the next pandemic is difficult, but influenza A(H7N9), which had not infected humans until 2013 but has since infected about 1,600 people in China and killed 37% of them, appears to have the greatest potential.

National influenza surveillance programs and influenza-related social media applications have been developed and may get a boost from technology. A smartphone equipped with a temperature sensor can instantly detect one’s temperature with great precision. A 2018 study suggested that a smartphone-driven thermometry application correlated well with national influenza-like illness activity and improved its forecast in real time and up to 3 weeks in advance.

Transmission
Humidity may not block transmission
Animal studies have suggested that humidity in the air interferes with transmission of airborne influenza virus, partially from biologic inactivation. But when a recent study used humidity-controlled chambers to investigate the stability of the 2009 influenza A(H1N1) virus in suspended aerosols and stationary droplets, the virus remained infectious in aerosols across a wide range of relative humidities, challenging the common belief that humidity destabilizes respiratory viruses in aerosols.

One sick passenger may not infect the whole plane
Transmission of respiratory viruses on airplane flights has long been considered a potential avenue for spreading influenza. However, a recent study that monitored movements of individuals on 10 transcontinental US flights and simulated inflight transmission based on these data showed a low probability of direct transmission, except for passengers seated in close proximity to an infectious passenger.

What’s in the new flu shot?
The 2018–2019 quadrivalent vaccine for the Northern Hemisphere contains the following strains:

<table>
<thead>
<tr>
<th>Year</th>
<th>Strain</th>
</tr>
</thead>
<tbody>
<tr>
<td>1918</td>
<td>Influenza A(H1N1) pandemic</td>
</tr>
<tr>
<td>1933</td>
<td>Isolation of influenza virus; development of first vaccine</td>
</tr>
<tr>
<td>1952</td>
<td>World Health Organization establishes the Global Influenza Surveillance Network</td>
</tr>
<tr>
<td>1957</td>
<td>Influenza A(H2N2) pandemic</td>
</tr>
<tr>
<td>1968</td>
<td>Influenza A(H3N2) pandemic; antiviral drugs developed</td>
</tr>
<tr>
<td>2009</td>
<td>Influenza A(H1N1) pandemic</td>
</tr>
<tr>
<td>2013</td>
<td>First non-egg-based vaccine</td>
</tr>
<tr>
<td>2018</td>
<td>Universal vaccine studies</td>
</tr>
</tbody>
</table>
MOSSAD

• A/Michigan/45/2015 A(H1N1)pdm09-like virus
• A/Singapore/INFIMH-16-0019/2016 (H3N2)-like virus
• B/Colorado/06/2017-like virus (Victoria lineage)
• B/Phuket/3073/2013-like virus (Yamagata lineage).

The A(H3N2) (Singapore) and B/Victoria lineage components are new this year. The A(H3N2) strain was the main cause of the 2018 influenza epidemic in the Southern Hemisphere.

The quadrivalent live-attenuated vaccine, which was not recommended during the 2016–2017 and 2017–2018 influenza seasons, has made a comeback and is recommended for the 2018–2019 season in people for whom it is appropriate based on age and comorbidities.15 Although it was effective against influenza B and A(H3N2) viruses, it was less effective against the influenza A(H1N1)pdm09-like viruses during the 2013–2014 and 2015–2016 seasons.

A/Slovenia/2903/2015, the new A(H1N1) pdm09-like virus included in the 2018–2019 quadrivalent live-attenuated vaccine, is significantly more immunogenic than its predecessor, A/Bolivia/559/2013, but its clinical effectiveness remains to be seen.

■ PROMOTING VACCINATION

How effective is it?
Influenza vaccine effectiveness in the 2017–2018 influenza season was 36% overall, 67% against A(H1N1), 42% against influenza B, and 25% against A(H3N2).16 It is estimated that influenza vaccine prevents 300 to 4,000 deaths annually in the United States alone.17

A 2018 Cochrane review17 concluded that vaccination reduced the incidence of influenza by about half, with 2.3% of the population contracting the flu without vaccination compared with 0.9% with vaccination (risk ratio 0.41, 95% confidence interval 0.36–0.47). The same review found that 71 healthy adults need to be vaccinated to prevent 1 from experiencing influenza, and 29 to prevent 1 influenza-like illness.

Several recent studies showed that influenza vaccine effectiveness varied based on age and influenza serotype, with higher effectiveness in people ages 5 to 17 and ages 18 to 64 than in those age 65 and older.18–20 A mathematical model of influenza transmission and vaccination in the United States determined that even relatively low-efficacy influenza vaccines can be very useful if optimally distributed across age groups.21

Vaccination rates are low, and ‘antivaxxers’ are on the rise
Although the influenza vaccine is recommended in the United States for all people age 6 months and older regardless of the state of their health, vaccination rates remain low. In 2016, only 37% of employed adults were vaccinated. The highest rate was for government employees (45%), followed by private employees (36%), followed by the self-employed (30%).22

A national goal is to immunize 80% of all Americans and 90% of at-risk populations (which include children and the elderly).23 The number of US hospitals that require their employees to be vaccinated increased from 37.1% in 2013 to 61.4% in 2017.24 Regrettably, as of March 2018, 14 lawsuits addressing religious objections to hospital influenza vaccination mandates have been filed.25

Despite hundreds of studies demonstrating the efficacy, safety, and cost savings of influenza vaccination, the antivaccine movement has been growing in the United States and worldwide.26 All US states except West Virginia, Mississippi, and California allow non-medical exemptions from vaccination based on religious or personal belief.27 Several US metropolitan areas represent “hot spots” for these exemptions.28 This may render such areas vulnerable to vaccine-preventable diseases, including influenza.

Herd immunity: We’re all in this together
Some argue that the potential adverse effects and the cost of vaccination outweigh the benefits, but the protective benefits of herd immunity are significant for those with comorbidities or compromised immunity.

Educating the public about herd immunity and local influenza vaccination uptake increases people’s willingness to be vaccinated.29 A key educational point is that at least 70% of a community needs to be vaccinated to
prevent community outbreaks; this protects everyone, including those who do not mount a protective antibody response to influenza vaccination and those who are not vaccinated.

■ DOES ANNUAL VACCINATION BLUNT ITS EFFECTIVENESS?

Some studies from the 1970s and 1980s raised concern over a possible negative effect of annual influenza vaccination on vaccine effectiveness. The “antigenic distance hypothesis” holds that vaccine effectiveness is influenced by antigenic similarity between the previous season’s vaccine serotypes and the epidemic serotypes, as well as the antigenic similarity between the serotypes of the current and previous seasons.

A meta-analysis of studies from 2010 through 2015 showed significant inconsistencies in repeat vaccination effects within and between seasons and serotypes. It also showed that vaccine effectiveness may be influenced by more than 1 previous season, particularly for influenza A(H3N2), in which repeated vaccination can blunt the hemagglutinin antibody response.30

A study from Japan showed that people who needed medical attention for influenza in the previous season were at lower risk of a similar event in the current season.31 Prior-season influenza vaccination reduced current-season vaccine effectiveness only in those who did not have medically attended influenza in the prior season. This suggests that infection is more immunogenic than vaccination, but only against the serotype causing the infection and not the other serotypes included in the vaccine.

An Australian study showed that annual influenza vaccination did not decrease vaccine effectiveness against influenza-associated hospitalization. Rather, effectiveness increased by about 15% in those vaccinated in both current and previous seasons compared with those vaccinated in either season alone.32

European investigators showed that repeated seasonal influenza vaccination in the elderly prevented the need for hospitalization due to influenza A(H3N2) and B, but not A(H1N1)pdm09.33

■ VACCINATION IN SPECIAL POPULATIONS

High-dose vaccine for older adults

The high-dose influenza vaccine has been licensed since 2009 for use in the United States for people ages 65 and older.

Recent studies confirmed that high-dose vaccine is more effective than standard-dose vaccine in veterans34 and US Medicare beneficiaries.35

The high-dose vaccine is rapidly becoming the primary vaccine given to people ages 65 and older in retail pharmacies, where vaccination begins earlier in the season than in providers’ offices.36 Some studies have shown that the standard-dose vaccine wanes in effectiveness toward the end of the influenza season (particularly if the season is long) if it is given very early. It remains to be seen whether the same applies to the high-dose influenza vaccine.

Some advocate twice-annual influenza vaccination, particularly for older adults living in tropical and subtropical areas, where influenza seasons are more prolonged. However, a recently published study observed reductions in influenza-specific hemagglutination inhibition and cell-mediated immunity after twice-annual vaccination.37

Vaccination is beneficial during pregnancy

Many studies have shown the value of influenza vaccination during pregnancy for both mothers and their infants.

One recently published study showed that 18% of infants who developed influenza required hospitalization.38 In that study, prenatal and postpartum maternal influenza vaccination decreased the odds of influenza in infants by 61% and 53%, respectively.

Another study showed that vaccine effectiveness did not vary by gestational age at vaccination.39

Some studies have shown that influenza virus infection can increase susceptibility to certain bacterial infections. A post hoc analysis of an influenza vaccination study in pregnant women suggested that the vaccine was also associated with decreased rates of pertussis in these women.40
Factors that make vaccination less effective
Several factors including age-related frailty and iatrogenic and disease-related immunosuppression can affect vaccine effectiveness.

Frailty. A recent study showed that vaccine effectiveness was 77.6% in nonfrail older adults but only 58.7% in frail older adults.41

Immunosuppression. Temporary discontinuation of methotrexate for 2 weeks after influenza vaccination in patients with rheumatoid arthritis improves vaccine immunogenicity without precipitating disease flare.42 Solid-organ and hematopoietic stem cell transplant recipients who received influenza vaccine were less likely to develop pneumonia and require intensive care unit admission.43 The high-dose influenza vaccine is more immunogenic than the standard-dose vaccine in solid-organ transplant recipients.44

Statins are widely prescribed and have recently been associated with reduced influenza vaccine effectiveness against medically attended acute respiratory illness, but their benefits in preventing cardiovascular events outweigh this risk.45

FUTURE VACCINE CONSIDERATIONS
Moving away from eggs
During the annual egg-based production process, which takes several months, the influenza vaccine acquires antigenic changes that allow replication in eggs, particularly in the hemagglutinin protein, which mediates receptor binding. This process of egg adaptation may cause antigenic changes that decrease vaccine effectiveness against circulating viruses.

The cell-based baculovirus influenza vaccine grown in dog kidney cells has higher antigenic content and is not subject to the limitations of egg-based vaccine, although it still requires annual updates. A recombinant influenza vaccine reduces the probability of influenza-like illness by 30% compared with...
the egg-based influenza vaccine, but also still requires annual updates.\textsuperscript{46} The market share of these non-egg-based vaccines is small, and thus their effectiveness has yet to be demonstrated.

The US Department of Defense administered the cell-based influenza vaccine to about one-third of Armed Forces personnel, their families, and retirees in the 2017–2018 influenza seasons, and data on its effectiveness are expected in the near future.\textsuperscript{47}

**A universal vaccine would be ideal**

The quest continues for a universal influenza vaccine, one that remains protective for several years and does not require annual updates.\textsuperscript{48} Such a vaccine would protect against seasonal epidemic influenza drift variants and pandemic strains. More people could likely be persuaded to be vaccinated once rather than every year.

The structure of the influenza virus can be depicted as a ball with spikes representing the hemagglutinin protein on its surface, each spike in the form of a stalk and a cap (Figure 1).\textsuperscript{49,50} All current influenza vaccines aim at the cap portion of the hemagglutinin protein. Annual antigenic drift of influenza viruses alters the cap portion of the hemagglutinin protein, requiring annual vaccine updates. The stalk portion of the hemagglutinin protein is consistent among different influenza viruses and is not altered annually like the cap portion. Thus, a vaccine aimed at the stalk portion of the hemagglutinin protein has the potential to be a universal vaccine.

An ideal universal vaccine would be suitable for all age groups, at least 75\% effective against symptomatic influenza virus infection, protective against all influenza A viruses (influenza A, not B, causes pandemics and seasonal epidemics), and durable through multiple influenza seasons.\textsuperscript{51}

Research and production of such a vaccine are expected to require funding of about $1 billion over the next 5 years.

**Boosting effectiveness**

Estimates of influenza vaccine effectiveness range from 40\% to 60\% in years when the vaccine viruses closely match the circulating viruses, and variably lower when they do not match. The efficacy of most other vaccines given to prevent other infections is much higher.

New technologies to improve influenza vaccine effectiveness are needed, particularly for influenza A(H3N2) viruses, which are rapidly evolving and are highly susceptible to egg-adaptive mutations in the manufacturing process.

In one study, a nanoparticle vaccine formulated with a saponin-based adjuvant induced hemagglutination inhibition responses that were even greater than those induced by the high-dose vaccine.\textsuperscript{52}

Immunoglobulin A (IgA) may be a more effective vaccine target than traditional influenza vaccines that target IgG, since different parts of IgA may engage the influenza virus simultaneously.\textsuperscript{53}

Vaccines can be developed more quickly than in the past. The timeline from viral sequencing to human studies with deoxyribonucleic acid plasmid vaccines decreased from 20 months in 2003 for the severe acquired respiratory syndrome coronavirus to 11 months in 2006 for influenza A/Indonesia/2006 (H5), to 4 months in 2009 for influenza A/California/2009 (H1), to 3.5 months in 2016 for Zika virus.\textsuperscript{54} This is because it is possible today to sequence a virus and insert the genetic material into a vaccine platform without ever having to grow the virus.

**TREATMENT**

Numerous studies have found anti-influenza medications to be effective. Nevertheless, in an analysis of the 2011–2016 influenza seasons, only 15\% of high-risk patients were prescribed anti-influenza medications within 2 days of symptom onset, including 37\% in those with laboratory-confirmed influenza.\textsuperscript{55} Fever was associated with an increased rate of antiviral treatment, but 25\% of high-risk outpatients were afebrile. Empiric treatment of 4 high-risk outpatients with acute respiratory illness was needed to treat 1 patient with influenza.\textsuperscript{55}

Treatment with a neuraminidase inhibitor within 2 days of illness has recently been shown to improve survival and shorten duration of viral shedding in patients with avian influenza A(H7N9) infection.\textsuperscript{56} Antiviral treatment within 2 days of illness is associated with improved outcomes in transplant recipients\textsuperscript{57} and with a lower risk of otitis media in children.\textsuperscript{58}
Appropriate anti-influenza treatment is as important as avoiding unnecessary antibiotics. Regrettably, as many as one-third of patients with laboratory-confirmed influenza are prescribed antibiotics.59

The US Food and Drug Administration warns against fraudulent unapproved over-the-counter influenza products.60

Baloxavir marboxil
Baloxavir marboxil is a new anti-influenza medication approved in Japan in February 2018 and anticipated to be available in the United States sometime in 2019.

This prodrug is hydrolyzed in vivo to the active metabolite, which selectively inhibits cap-dependent endonuclease enzyme, a key enzyme in initiation of messenger ribonucleic acid synthesis required for influenza viral replication.61

In a double-blind phase 3 trial, the median time to alleviation of influenza symptoms is 26.5 hours shorter with baloxavir marboxil than with placebo. One tablet was as effective as 5 days of the neuraminidase inhibitor oseltamivir and was associated with greater reduction in viral load 1 day after initiation, and similar side effects.62 Of concern is the emergence of nucleic acid substitutions conferring resistance to baloxavir; this occurred in 2.2% and 9.7% of baloxavir recipients in the phase 2 and 3 trials, respectively.

■ CLOSING THE GAPS
Several gaps in the management of influenza persist since the 1918 pandemic.1 These include gaps in epidemiology, prevention, diagnosis, treatment, and prognosis.

■ REFERENCES
MOSSAD


ADDRESS: Sherif Beniameen Mossad, MD, Department of Infectious Diseases, G21, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; mossads@ccf.org

Cleveland Clinic

R.J. Fasenmyer Center for Clinical Immunology

7th Annual Basic and Clinical Immunology for the Busy Clinician: What Is New and Hot in Immunology

An Immunology Boot Camp

February 15-16, 2019

Saguaro Scottsdale, Scottsdale, AZ

Register now! ccfcmeforclinical19

Never has a conference been so specifically tailored to bridge the bench to the bedside and beyond!

Register to attend a one-of-a-kind symposium with a unique array of educational offerings in the field of clinical immunology – designed for busy clinicians caring for patients with IMIDs who desire to increase their declarative and procedural knowledge in the field as it applies to patient care.

This activity has been approved for AMA PRA Category 1 Credit™.